BioWorld

Oct. 21, 2005

Amgen Beats Estimates But Drops On Revenue Numbers

Reporting a 19 percent increase in product sales over last year, Amgen Inc. topped consensus estimates for the three months ending Sept. 30, though its revenue fell short of expectations. (BioWorld Today) Read More

Lay Press, Drug Withdrawals Adding Squeeze To Industry

Alinea Brings In $45M For Diabetes, Metabolic Programs

Cardium Acquires Portfolio From Schering, Raises $28.5M

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...